CNBX Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is September - August.

Millions USD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Aug '25 Aug 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021
Revenue	-	-	0.13	0.41	0.03	-
Revenue Growth (YoY)	-	-	-68.29%	1269.13%	-	-
Gross Profit	-	-	0.13	0.41	0.03	-
Selling, General & Admin	0.31	0.27	0.52	0.91	1.8	0.83
Research & Development	-	-	0.19	0.43	1.18	1.77
Operating Expenses	0.31	0.27	0.71	1.34	2.98	2.6
Operating Income	-0.31	-0.27	-0.58	-0.93	-2.95	-2.6
Interest Expense	-0.04	-0.04	-0.02	-0	-0	-0
Currency Exchange Gain (Loss)	-0	-0	-0	0	-0.06	-0.02
Other Non Operating Income (Expenses)	-0.02	-	-	-0.05	-0.72	-0.96
EBT Excluding Unusual Items	-0.37	-0.31	-0.61	-0.98	-3.74	-3.59
Gain (Loss) on Sale of Investments	-	-	-	-	-	0.2
Gain (Loss) on Sale of Assets	-	-	-0.09	-2.73	0.01	0.2
Pretax Income	-0.37	-0.31	-0.7	-3.71	-3.72	-3.19
Net Income	-0.37	-0.31	-0.7	-3.71	-3.72	-3.19
Net Income to Common	-0.37	-0.31	-0.7	-3.71	-3.72	-3.19
Shares Outstanding (Basic)	490	91	30	9	1	1
Shares Outstanding (Diluted)	490	91	30	9	1	1
Shares Change (YoY)	1459.86%	199.69%	242.76%	621.77%	5.92%	2.95%
EPS (Basic)	-0.00	-0.00	-0.02	-0.42	-3.05	-2.77
EPS (Diluted)	-0.00	-0.00	-0.02	-0.42	-3.05	-2.77
Free Cash Flow	-0.16	-0.17	-0.25	-0.11	-1.68	-2.49
Free Cash Flow Per Share	-	-0.00	-0.01	-0.01	-1.38	-2.16
Gross Margin	-	-	100.00%	100.00%	100.00%	-
Operating Margin	-	-	-448.31%	-227.07%	-9860.37%	-
Profit Margin	-	-	-534.46%	-904.57%	-12428.23%	-
Free Cash Flow Margin	-	-	-188.71%	-27.43%	-5610.68%	-
EBITDA	-	-0.2	-0.51	-0.77	-2.76	-2.38
EBITDA Margin	-	-	-	-187.56%	-	-
D&A For EBITDA	-	0.07	0.07	0.16	0.2	0.22
EBIT	-0.31	-0.27	-0.58	-0.93	-2.95	-2.6
EBIT Margin	-	-	-	-227.07%	-	-

Updated Feb 28, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.